DC Field | Value | Language |
dc.contributor.author | Ghilascu, Cornelia | |
dc.date.accessioned | 2020-09-29T14:52:27Z | |
dc.date.available | 2020-09-29T14:52:27Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | GHILASCU, Cornelia. Non-invasive diagnosis of hepatic fibrosis. In: MedEspera: the 8th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2020, p. 273-274. | en_US |
dc.identifier.uri | https://medespera.asr.md/wp-content/uploads/ABSTRACT-BOOK.pdf | |
dc.identifier.uri | http://repository.usmf.md/handle/20.500.12710/11798 | |
dc.description | Department of
Biochemistry and Clinical Biochemistry, Nicolae Testemitanu State University of Medicine
and Pharmacy, Chisinau, Republic of Moldova, The 8th International Medical Congress for Students and Young Doctors, September 24-26, 2020 | en_US |
dc.description.abstract | Introduction. Hepatic fibrosis is a worldwide health issue, whose prognosis; management and
potential treatment depend on establishing the accurate diagnosis according to the progression
of the disease. Modern medicine studies efficient, safe and non-invasive methods for the
assessment of hepatic fibrosis, such as serum biomarkers and imaging techniques: FibroScan
elastometry, MRI, ARFI.Aim of the study. Identification and study of the non-invasive methods for the diagnosis of
hepatic fibrosis
Materials and methods. A bibliographic study of scientific literature from 2009-2020 based
on Biomed Central, Bio Predictive, ACS Publications data bases was done, with the following
search words – hepatic fibrosis, non-invasive diagnosis, fibrotest, biomarker of fibrosis.
Results. Serum biomarkers, used for the assessment of hepatic fibrosis, are classified in: direct
biomarkers – Procollagen type I carboxy-terminal peptide (PICP), Procollagen type III aminoterminal
peptide (PIIINP), matrix metalloproteinases (MMPs), tissue inhibitors of matrix
metalloproteinases (TIMPs), hyaluronic acid (HA), transforming growth factor β1 (TGFβ1),
laminin, connective tissue growth factor (CTGF); and indirect biomarkers – AST/ALT ratio,
coagulation factors, platelet count, γ2-macroglobulin, γ2-globulin, γ-globulin, apolipoprotein
A1, GGT, total bilirubin. These serum biomarkers are combined in non-invasive scores such
as APRI, FibroTest, FIB-4. Transient Ultrasound Elastography or FibroScan measures liver
stiffness (elasticity) and allows determining the stage of hepatic fibrosis according to
METAVIR score: F1, F2, F3, and F4. MRI can be used to measure hepatic stiffness, and at the
same time other associated pathologies.Conclusions. Management and individualized treatment of hepatic fibrosis depend on
establishing an accurate stage diagnosis. Non-invasive methods, serum biomarkers and
imaging techniques allow to determine a correct diagnosis and at the same time to minimize
the complications. FibroTest, FibroScan and APRI score are methods that showed the highest
clinical efficiency. However, recent studies are focused on identifying the correlation between
tissue modifications, the results of serum biomarkers and FibroTest, FibroScan and APRI
score. | en_US |
dc.language.iso | en | en_US |
dc.publisher | MedEspera | en_US |
dc.subject | hepatic fibrosis | en_US |
dc.subject | non-invasive methods | en_US |
dc.subject | FibroTest | en_US |
dc.subject | FibroScan | en_US |
dc.subject | APRI | en_US |
dc.subject | biomarker of fibrosis | en_US |
dc.title | Non-invasive diagnosis of hepatic fibrosis | en_US |
dc.type | Article | en_US |
Appears in Collections: | MedEspera 2020
|